Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of ACARIZAX allergen immunotherapy on antiviral immunity in allergic asthma
2019-003261-18Phase 4Completed
- Start
- Sep 2019
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic asthma comparing ACARIZAX with Placebo (2 arms). Primary endpoints: Primary: Change in interferon-beta gene expression and Primary: Change in interferon-beta protein expression. Started Sep 2019; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2019-003261-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003261-18.